a2

1. A compound of the formula (I):



wherein R^1 is a 5- to 6- membered aromatic ring which has a group of the formula:

$R\text{-}Z^1\text{-}X\text{-}Z^2\text{-}$

wherein R is a hydrogen atom or a substituted or unsubstituted hydrocarbon group,

X is a substituted or unsubstituted alkylene chain, and

Z^1 and Z^2 are respectively hetero-atoms, and which may have a further substituent,

the group R may bind to the 5- to 6- membered aromatic ring to form a ring,

Y is a substituted or unsubstituted imino group,

R^2 and R^3 are respectively a substituted or unsubstituted aliphatic hydrocarbon group or a substituted or unsubstituted alicyclic heterocyclic group;

or a salt thereof.

✓

a3

4. The compound according to claim 1, wherein the 5- to 6-membered aromatic ring is benzene.

[redacted]

contd. a3

5. The compound according to claim 1, wherein R is a halogenated or unhalogenated lower alkyl group.

6. The compound according to claim 1, wherein X is $-(CH_2)_n-$

wherein n is an integer of 1-4.

7. The compound according to claim 1, wherein Z^1 and Z^2 are respectively –O-, $-S(O)_m-$

wherein m is an integer of 0-2 or $-N(R^4)-$

wherein R^4 is a hydrogen atom or an optionally substituted lower alkyl group.

8. The compound according to claim 1, wherein Z^1 is -O- or $-S(O)_m-$

wherein m is an integer of 0-2.

a4

10. The compound according to claim 1, wherein Z^2 is –O- or $-N(R^4)-$

wherein R^4 is a hydrogen atom or a substituted or unsubstituted lower alkyl group.

a5

12. The compound according to claim 1, wherein Y is $-N(R^5)-$

wherein R^5 is a hydrogen atom, a substituted or unsubstituted hydrocarbon group or a substituted or unsubstituted acyl group.

13. The compound according to claim 12, wherein R^5 is C_{1-4} alkyl, formyl or C_{2-5} alkanoyl.

14. The compound according to claim 12, wherein R^5 is a group represented by the formula $-(CH_2)_k-R^6$; wherein k is 0 or 1, and R^6 is a substituted or unsubstituted 5- to 6- membered monocylic aromatic group.

15. The compound according to claim 1, wherein R^2 is a substituted or unsubstitued straight

contd.

a5

chain hydrocarbon group.

16. The compound according to claim 1, wherein R^2 is an optionally substituted lower alkyl group.

17. The compound according to claim 1, wherein R^3 is a substituted or unsubstituted alicyclic hydrocarbon group or a substituted or unsubstituted alicyclic heterocyclic group.

a6

23. A compound selected from the group consisting of 7-(4-ethoxyethoxyphenyl)-1-ethyl-N-[4-[[N-methyl-N-(tetrahydropyran-4-yl)amino]methyl]phenyl]-2,3-dihydro-1-benzazepine-4-carboxamide, 1-ethyl-7-(4-propoxyethoxyphenyl)-N-[4-[[N-methyl-N-(tetrahydropyan-4-yl)amino]methyl]phenyl]-2,3-dihydro-1-benzazepine-4-carboxamide, 7-(4-butoxyethoxyphenyl)-1-ethyl-N-[4-[[N-methyl-N-(tetrahydropyran-4-yl)amino]methyl]phenyl]-2,3-dihydro-1-benzazepine-4-carboxamide, 7-(4-ethoxyethoxyphenyl)-1-formyl-N-[4-[[N-methyl-N-(tetrahydropyran-4-yl)amino]methyl]phenyl]-2,3-dihydro-1-benzazepine-4-carboxamide, 1-formyl-7-(4-propoxyethoxyphenyl)-N-[4-[[N-methyl-N-(tetrahydropyran-4-yl)amino]methyl]phenyl]-2,3-dihydro-1-benzazepine-4-carboxamide, 7-(4-butoxyethoxyphenyl)-1-formyl-N-[4-[[N-methyl-N-(tetrahydropyran-4-yl)amino]methyl]phenyl]-2,3-dihydro-1-benzazepine-4-carboxamide, 7-(4-butoxyethoxyphenyl)-N-[4-[[N-methyl-N-(tetrahydropyran-5-yl)amino]methyl]phenyl]-1-propyl-2,3-dihydro-1-benzazepine-4-carboxamide, N-[4-[[N-methyl-N-(tetrahydropyran-5-yl)amino]methyl]phenyl]-7-(4-propoxyethyoxyphenyl)-1-propyl-2,3-dihydro-1-benzazepine-4-carboxamide, 1-benzyl-7-(4-butoxyethoxyphenyl)-N-[4-[[N-methyl-N-(tetrahydropyran-4-yl)amino]methyl]phenyl]-2,3-dihydro-1-benzazepine-4-carboxamide, 7-(4-butoxyethoxyphenyl)-1-cyclopropylmethyl-N-[4-[[N-methyl-N-(tetrahydropyan-4-yl)amino]methyl]phenyl]-2,3-dihydro-1-benzazepine-4-carboxamide, 7-

contd. a6

(4-butoxyethoxyphenyl)-N-[4-[[N-methyl-N-(tetrahydropyran-4-yl)amino]methyl]phenyl]-1-phenyl-2,3-dihydro-1-benzazepine-4-carboxamide, 7-(4-butoxyethoxyphenyl)-1-(3,4-methylenedioxy)phenyl-N-[4-[[N-methyl-N-(tetrahydropyran-4-yl)amino]methyl]phenyl]-2,3-dihydro-1-benzazepine-4-carboxamide, 7-(4-butoxyethoxyphenyl)-1-(2-methyloxazol-5-yl)-N-[4-[[N-methyl-N-(tetrahydropyran-4-yl)amino]methyl]phenyl]-2,3-dihydro-1-benzazepine-4-carboxamide, 1-allyl-7-(4-butoxyethoxyphenyl)-N-[4-[[N-methyl-N-(tetrahydropyran-4-yl)amino]methyl]phenyl]-2,3-dihydro-1-benzazepine-4-carboxamide, 7-(4-butoxyethoxyphenyl)-N-[4-[[N-methyl-N-(tetrahydropyran-4-yl)amino]methyl]phenyl]-1-(3-thienyl)methyl-2,3-dihydro-1-benzazepine-4-carboxamide, 7-(4-butoxyethoxyphenyl)-N-[4-[[N-methyl-N-(tetrahydropyran-4-yl)amino]methyl]phenyl]-1-(thiazol-2-yl)methyl-2,3-dihydro-1-benzazepine-4-carboxamide, 7-(4-butoxyethoxyphenyl)-1-(1-methylpyrazol-4-yl)methyl-N-[4-[[N-methyl-N-(tetrahydropyran-4-yl)amino]methyl]phenyl]-2,3-dihydro-1-benzazepine-4-carboxamide, 7-(4-butoxyethoxyphenyl)-1-(3-methylisothiazol-4-yl)methyl-N-[4-[[N-methyl-N-(tetrahydropyran-5-yl)amino]methyl]phenyl]-2,3-dihydro-1-benzazepine-4-carboxamide, 7-(4-butoxyethoxyphenyl)-1-(1-ethylpyrazol-4-yl)methyl-N-[4-[[N-methyl-N-(tetrahydropyran-4-yl)amino]methyl]phenyl]-2,3-dihydro-1-benzazepine-4-carboxamide, 7-(4-butoxyethoxyphenyl)-1-isobutyl-N-[4-[[N-methyl-N-(tetrahydropyran-5-yl)amino]methyl]phenyl]-2,3-dihydro-1-benzazepine-4-carboxamide, 1-isobutyl-N-[4-[[N-methyl-N-(tetrahydropyran-5-yl)amino]methyl]phenyl]-7-(4-propoxyethoxyphenyl)-2,3-dihydro-1-benzazepine-4-carboxamide, 7-(4-butoxyethoxyphenyl)-N-[4-[[N-methyl-N-(tetrahydropyran-4-yl)amino]methyl]phenyl]-1-(thiazol-5-yl)methyl-2,3-dihydro-1-benzazepine-4-carboxamide, 7-(4-butoxyethoxyphenyl)-N-[4-[[N-methyl-N-(tetrahydropyran-4-yl)amino]methyl]phenyl]-1-(1-methyltetrazol-5-yl)methyl-2,3-dihydro-1-benzazepine-4-carboxamide, 7-(4-butoxyethoxyphenyl)-N-[4-[[N-methyl-N-(tetrahydropyran-4-yl)amino]methyl]phenyl]-1-(2-methyltetrazol-5-yl)methyl-2,3-dihydro-

1-benzazepine-4-carboxamide and salts thereof.

25. A method for producing a compound of the formula I:



wherein R^1 is a 5- to 6- membered aromatic ring which has a group of the formula:

$R\text{-}Z^1\text{-}X\text{-}Z^2\text{-}$

wherein R is a hydrogen atom or a substituted or unsubstituted hydrocarbon group,

X is a substituted or unsubstituted alkylene chain, and

Z^1 and Z^2 are respectively hetero-atoms, and which may have a further substituent,

the group R may bind to the 5- to 6- membered aromatic ring to form a ring,

Y is a substituted or unsubstituted imino group,

R^2 and R^3 are respectively a substituted or unsubstituted aliphatic hydrocarbon group or a substituted or unsubstituted alicyclic heterocyclic group;

or a salt thereof, which comprises subjecting a

contd.
a7

compound of the formula:



wherein R^1 and Y are as defined above, a salt or reactive derivative thereof to a condensation reaction with a compound of the formula:



wherein R^2 and R^3 are as defined above, or a salt thereof;

and then optionally isolating said compound of formula I or a salt thereof.

26. A pharmaceutical composition which comprises the compound according to claim 1 or a salt thereof and a pharmaceutically acceptable carrier, excipient, binder or diluent.

a8

29. The composition according to claim 26, which is for the treatment of infectious diseases of HIV.

30. The composition according to claim 26, which for the treatment of AIDS.

a9

35. A method for treating infectious diseases of HIV comprising administering

a pharmaceutically effective amount of a compound of claim 1 or a salt thereof

in combination with a protease inhibitor, a reverse transcriptase inhibitor or a combination thereof

contd.
a9

to a mammal in need thereof.

✓

a10 37. A method for treating AIDS comprising administering a pharmaceutically effective amount of a compound of claim 1 or a salt thereof to a mammal in need thereof.